Test For Named Disease, Body Condition Or Organ Function Patents (Class 436/811)
  • Patent number: 10060932
    Abstract: Methods for identifying metabolic signatures in blood plasma which are unique to autism are described herein. Samples are analyzed using multiple chromatographic-mass spectrometry-based techniques to orthogonally measure a broad range of small molecular weight metabolites differentially produced in autistic patient samples versus non-autistic control samples. These individual metabolites or a panel of such metabolites serve as metabolic signatures of autism. Such metabolic signatures are used in diagnostic methods to accurately identify individuals with autism spectrum disorder (ASD).
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: August 28, 2018
    Assignee: Stemina Biomarker Discovery, Inc.
    Inventors: Paul West, Robert E. Burrier, Laura Egnash, Alan Smith, Preeti Bais
  • Patent number: 9040308
    Abstract: Management of the health status of an animal colony using a plurality of blood collection cards and the analysis of dried blood from members of the colony that has been collected on the cards. Members of the colony may be removed from the colony as a result of the analysis.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: May 26, 2015
    Assignee: IDEXX Laboratories, Inc.
    Inventor: Matthew Howard Myles
  • Patent number: 9017957
    Abstract: An object of the present invention is to provide an antibody that can be stably supplied and can react with prostasin under non-denaturation and denaturation conditions, and an antigen peptide for preparation of the antibody. The present invention relates to a peptide consisting of the amino acid sequence shown in SEQ ID NO: 1 or a peptide consisting of an amino acid sequence that has a deletion, a substitution, or an addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1 and having antigenicity of prostasin. Furthermore, the present invention relates to an antibody prepared using the peptide as an antigen.
    Type: Grant
    Filed: May 1, 2007
    Date of Patent: April 28, 2015
    Assignees: Hitachi Chemical Company, Ltd., Kimio Tomita, Kenichiro Kitamura
    Inventors: Hiromi Iijima, Noriya Ohta, Kimio Tomita, Kenichiro Kitamura
  • Patent number: 9012162
    Abstract: The inventors have proposed a novel panel of human serum protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis. A 2D-PAGE based proteomics study was used to identify potential fibrosis biomarkers. Serum from patients with varying degrees of hepatic scarring induced by infection with the hepatitis C virus (HCV) was analyzed. Several proteins associated with liver scarring and/or viral infection were identified. These proteins include the inter-?-trypsin inhibitor heavy chain H4 fragments, complement factor H-related protein 1, CD5L, Apo L1, and ?2GPI. Increased and decreased thiolester cleavage of a2M and Complement C3, respectively, was also detected. The concentrations of these novel biomarkers can be determined using an immunoassay where the concentrations would reflect the extent of fibrosis. A fibrosis scoring scale for each of the novel biomarkers is proposed.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: April 21, 2015
    Assignee: The Chancellor, Masters and Scholars of The University of Oxford
    Inventors: Bevin Gangadharan, Nicole Zitzmann, Raymond A. Dwek
  • Patent number: 8986936
    Abstract: The present invention relates to methods and kits for the prediction of risk for heart failure using post-translation modified forms of cardiac troponin T as a biomarker.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: March 24, 2015
    Assignees: Inserm (Institut National de la Santa et de la Recherche Medicale), Institute Pasteur de Lille, Le Centre Hospitalier Regional Universitaire de Lille, Universite de Rouen
    Inventors: Florence Pinet, Paul Mulder, Christophe Bauters, Vincent Richard
  • Patent number: 8945945
    Abstract: Management of the health status of an animal colony using a plurality of blood collection cards and the analysis of dried blood from members of the colony that has been collected on the cards. Members of the colony may be removed from the colony as a result of the analysis.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: February 3, 2015
    Assignee: IDEXX Laboratories, Inc.
    Inventor: Matthew Howard Myles
  • Patent number: 8927298
    Abstract: Management of the health status of an animal colony using a plurality of blood collection cards and the analysis of dried blood from members of the colony that has been collected on the cards. Members of the colony may be removed from the colony as a result of the analysis.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: January 6, 2015
    Assignee: IDEXX Laboratories, Inc.
    Inventor: Matthew H. Myles
  • Patent number: 8927220
    Abstract: A protein used as a biomarker for diagnosing IgA nephropathy and TGBM (thin-glomerular-basement-membrane) using urine through a target proteomics method. A diagnosis biomarker protein and a kit for diagnosing IgA nephropathy and TGBM and predicting progress of the nephropathy in advance using the protein are provided. The degree of the progression of the disease can be grasped by detecting IgA nephropathy and TGBM, enabling early diagnosis and confirming progress from the patient's urine. In addition, a monoclonal antibody produced based on the diagnosis biomarker protein can be used for an immunoassay kit (ELISA, antibody coated tube test, lateral-flow test, potable biosensor). The monoclonal antibody is used in early diagnosis and progression detection of IgA nephropathy and development of a novel drug for the purpose of treatment.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: January 6, 2015
    Assignee: Kyungpook National University Industry-Academic Cooperation Foundation
    Inventors: Moon Chang Baek, Pyong Gon Moon, Yong Lim Kim
  • Patent number: 8916388
    Abstract: In vitro multiparameter method for the diagnosis and early diagnosis, for determination of the severity and for assessing the course and prognosis of neurodegenerative disorders, in which the concentrations of at least two different vasotropic peptides are determined in a biological fluid from a person suffering from subjective or objectively detectable cognitive impairments, the resulting person-specific measurements are combined computationally to give a person-specific complex reference value, and conclusions are drawn concerning the presence of a neurodegenerative disorder in the person on the basis of the person-specific complex reference value found.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: December 23, 2014
    Assignee: Sphingotec GmbH
    Inventors: Andreas Bergmann, Andrea Ernst, Harald Hampel
  • Patent number: 8900881
    Abstract: The present invention relates to a quantitative assay device and a method for the determination of an analyte, based on a test strip, which contains a porous test membrane allowing for capillary flow of the analyte and complexes of the analyte, a porous upstream membrane in fluid connection with the test membrane and a porous downstream membrane in fluid connection with the test membrane, wherein the test membrane contains two bands having deposited on there high and low concentrations of different calibrator agents and a test band capable of reacting with conjugated analyte complexes giving rise to a measurable signal.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: December 2, 2014
    Inventor: Jin Po Lee
  • Patent number: 8846413
    Abstract: Products and methods for the research, diagnosis, risk assessment, course monitoring, treatment and prophylaxis of various metabolic disorders and their early forms, concomitant diseases and secondary diseases are provided. Metabolic diseases include, for example, metabolic syndrome, non-insulin-dependent diabetes, (type II diabetes), insulin resistance, obesity (adiposis), in addition to diseases that are associated with disorders of the fatty acid metabolism. Methods may include analysis of the concentration of the adipocytic form of the fatty acid binding protein (A-FABP, FABP 4, P2) in various bodily fluids.
    Type: Grant
    Filed: July 21, 2006
    Date of Patent: September 30, 2014
    Assignee: Biovendor Laboratory Medicine, Inc.
    Inventor: Viktor Ruzicka
  • Patent number: 8765392
    Abstract: The present invention relates to methods and kits for diagnosing, ascertaining the clinical course of myelodysplastic syndrome (MDS) and ascertaining response to a therapy regimen of myelodysplastic syndrome. Specifically the invention provides methods and kits useful in the diagnosis and determination of clinical parameters associated with MDS based on surface markers unique to MDS.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: July 1, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Jonni Moore, Sundhu Cherian, Adam Bagg
  • Patent number: 8759018
    Abstract: A method for determining an appropriate treatment option for a patient who has been diagnosed with disseminated intravascular coagulation (DIC) but who may have thrombotic thrombocytopenic purpura (TTP), by analyzing the amount and/or enzyme activity of a von Willebrand factor (vWF)-cleaving protease (ADAMTS13) and the amount of vWF in a patient that has been diagnosed with DIC is disclosed. Using the method of the present invention, a differential diagnosis of patients with thrombotic thrombocytopenic purpura (TTP) can be made from among patients diagnosed with DIC, which could not previously be distinguished on the basis of only clinical findings or known markers. Also disclosed is a kit for determining an appropriate treatment option, the kit comprising an antibody or a fragment thereof which specifically binds to ADAMTS13.
    Type: Grant
    Filed: February 18, 2011
    Date of Patent: June 24, 2014
    Assignees: Mitsubishi Chemical Medience Corporation, Juridical Foundation the Chemo-Sero-Therapeutic Research Institute
    Inventors: Tomoko Ono, Shinichiro Watanabe, Fumio Furusaki, Ko Igami
  • Patent number: 8741662
    Abstract: Methods and kits for diagnosis and prognosis using biomarkers comprising albumin-bound protein/peptide complex (ABPPC).
    Type: Grant
    Filed: June 14, 2007
    Date of Patent: June 3, 2014
    Assignee: The Johns Hopkin University
    Inventors: Jennifer E. Van Eyk, Rebekah Lynn Gundry, Robert J. Cotter
  • Patent number: 8741580
    Abstract: The present invention relates to methods of detecting renal transplant rejection and other forms of renal damage. Protein markers or renal damage are provided, along with assays for detecting said markers. Also provided are methods for identifying markers of renal damage.
    Type: Grant
    Filed: September 20, 2011
    Date of Patent: June 3, 2014
    Assignee: Electrophoretics Limited
    Inventors: Stefan Kienle, Richard Joubert
  • Patent number: 8716030
    Abstract: Embodiments of the present invention provide for novel peptides of use for detection and/or inhibition of anti-?1-adrenergic receptor antibodies. Certain embodiments concern uses of cyclic and/or linear peptides. In other embodiments, the present invention relates to novel peptides of use in diagnostic and/or pharmaceutical compositions. Some embodiments concern diagnosing and/or treating cardiac conditions. Cardiac conditions of the instant invention can concern infectious heart disease, non-infectious heart disease, ischemic heart disease, non-ischemic heart disease, inflammatory heart disease, myocarditis, cardiac dilatation, idiopathic cardiomyopathy, idiopathic dilated cardiomyopathy, immune-cardiomyopathy, heart failure, and any cardiac arrhythmia condition.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: May 6, 2014
    Assignee: Julius-Maximillians-Universitat Wurzburg, A Germany University
    Inventors: Roland Jahns, Valérie Jahns, Martin J. Lohse, Dieter Palm
  • Patent number: 8715682
    Abstract: Embodiments of the present invention provide for novel peptides of use for detection and/or inhibition of anti-?1-adrenergic receptor antibodies. Certain embodiments concern uses of cyclic and/or linear peptides. In other embodiments, the present invention relates to novel peptides of use in diagnostic and/or pharmaceutical compositions. Some embodiments concern diagnosing and/or treating cardiac conditions. Cardiac conditions of the instant invention can concern infectious heart disease, non-infectious heart disease, ischemic heart disease, non-ischemic heart disease, inflammatory heart disease, myocarditis, cardiac dilatation, idiopathic cardiomyopathy, idiopathic dilated cardiomyopathy, immune-cardiomyopathy, heart failure, and any cardiac arrhythmia condition.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: May 6, 2014
    Assignee: Julius-Mazimillians-Universitat Wurzburg, a German University
    Inventors: Roland Jahns, Valérie Jahns, Martin J. Lohse, Dieter Palm
  • Patent number: 8715951
    Abstract: Disclosed are antibodies that selectively bind to blood coagulation factor FVIII, and highly sensitive immunological assays comprising these antibodies. Preferred assays can detect FVIII at about 3500-fold below the normal physiological levels, and have a wide array of applications including accurate monitoring of FVIII concentration in pharmaceutical products for treatment of blood coagulation disorders, and determination of FVIII levels in plasma of human patients, including those with blood coagulation disorders such as hemophilia.
    Type: Grant
    Filed: July 18, 2012
    Date of Patent: May 6, 2014
    Assignee: The University of Vermont and State Agriculture College
    Inventors: Behnaz Parhami-Seren, Kenneth G. Mann, David N. Fass
  • Patent number: 8709736
    Abstract: The present invention relates to the use of TFF3 in the diagnosis and detection of Barrett's esophagus using non-invasive, non-endoscopic methods.
    Type: Grant
    Filed: July 9, 2010
    Date of Patent: April 29, 2014
    Assignee: Medical Research Council
    Inventors: Pierre Lao-Sirieix, Rebecca C. Fitzgerald
  • Patent number: 8691585
    Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: April 8, 2014
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: John F. O'Connor, Galina I. Kovalevskaya, Steven Birken
  • Patent number: 8685662
    Abstract: The present invention pertains to a method for in vitro prognosticating and/or diagnosing cerebral cerebral malaria, wherein said method comprises a step of detecting non-erythroid spectrin or fragments thereof, and/or antibodies directed against non-erythroid spectrin, in a biological sample. Reagents and kits for performing this method are also disclosed.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: April 1, 2014
    Assignees: Institut Pasteur, Universite Pierre et Marie Curie (Paris 6)
    Inventors: Sylviane Pied, Vincent Guiyedi, Pierre-André Cazenave, Maryvonne Kombila, Youri Chanseaud
  • Patent number: 8673647
    Abstract: According to the method of evaluating stress of the present invention, amino acid concentration data on the concentration value of amino acid in blood collected from a subject to be evaluated is measured, and a stress state including at least depressive illness and major depressive illness in the subject is evaluated based on the concentration value of at least one of Lys, His, ABA, Asn, Phe, Leu, Ile, Val, Trp, Tyr and Met contained in the measured amino acid concentration data of the subject.
    Type: Grant
    Filed: February 4, 2009
    Date of Patent: March 18, 2014
    Assignee: Ajinomoto Co., Inc.
    Inventors: Takayuki Tanaka, Yukio Nihei, Toshihiko Ando, Minoru Yamakado, Keita Takamatsu, Eiko Takahashi, Norio Sasamori
  • Patent number: 8632991
    Abstract: Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) is administered to a subject to enhance blood coagulation in the subject. Also provided are methods for preparing a NASP composition having blood coagulation enhancing activity. Compositions and kits for practicing methods of the invention are also described.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: January 21, 2014
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Michael Dockal, Hartmut Ehrlich, Friedrich Scheiflinger
  • Patent number: 8628724
    Abstract: Methods and systems to collect a sample of bodily fluid from a patient using an integrated needle and test strip assembly are provided. In this novel assembly, the test strip and needle form one unit that captures the sample of blood or interstitial fluid from the patient once the apparatus is pressed to the skin. The hollow aspiration needle includes more than one opening at a distal end, each opening coming into contact with the bodily fluid when disposed within a cutaneous or subcutaneous layer of the patient's skin. The disclosed test strip includes at least one reaction site for testing analyte concentrations and a means for linking to many commercially available test strip meters to provide readout of the analyte concentration. The sample may be captured by capillary flow, by an integrated aspirator, or by a differential vacuum device resident on the test strip meter.
    Type: Grant
    Filed: January 3, 2012
    Date of Patent: January 14, 2014
    Assignee: Charleston Area Medical Center, Inc.
    Inventor: J. Todd Kuenstner
  • Patent number: 8609432
    Abstract: Disclosed is a rapid, non-invasive and highly specific and sensitive diagnostic assay for the identification of individuals with autoimmune chronic urticaria, which makes use of CD203c, and in some embodiments, additional proteins, as a marker for the disease. Test kits for diagnosis of an individual suspected of having autoimmune chronic urticaria are also disclosed. Also disclosed are a method of identifying compounds useful for treating autoimmune chronic urticaria and a method of treating autoimmune chronic urticaria.
    Type: Grant
    Filed: August 7, 2012
    Date of Patent: December 17, 2013
    Inventors: Ronald Joseph Harbeck, Karen Mary Andrews, Donald MacGlashan
  • Patent number: 8609356
    Abstract: The invention relates to an in vitro method for detecting pulmonary arterial hypertension (PAHT), or the risk of developing PAHT, which includes determining the presence and/or amount of anti-tenascin C antibodies in a biological sample from a patient.
    Type: Grant
    Filed: April 10, 2009
    Date of Patent: December 17, 2013
    Assignees: Assistance Publique-Hopitaux de Paris, Universite Paris Descartes, Universite Paris-Sud 11
    Inventors: Luc Mouthon, Marc Humbert, Mathieu Tamby
  • Patent number: 8609355
    Abstract: Methods, devices, and kits are provided herein for the accurate and rapid detection of disease causing microbes in a sample by the detection of microbial components of which correlate to the presence of the microbe. Kits include a first binding agent operatively coupled to an immobilized support; and a second binding agent operatively coupled to one or more pH indicating moieties wherein the first and second binding agents bind with sufficient specificity to the microbial component to permit detection of that component which correlates to the presence of the microbe in the sample.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: December 17, 2013
    Assignee: Indicator Systems International, Inc.
    Inventors: Gerald F. Swiss, Laurie B. F. Stellman
  • Patent number: 8603828
    Abstract: Hemoglobin, its variants, and glycated forms of each are determined individually in a multiplex assay that permits correction of the measured level of HbA1c to account for glycated variants and other factors related to the inclusion of the variants in the sample. New antibodies that are particularly well adapted to the multiplex assay are also provided.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: December 10, 2013
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Roger Walker, Benedicte Jardin
  • Patent number: 8568994
    Abstract: The invention discloses a method of prenatal diagnosis comprising the step of isolating exosomes from an isolated fluid, wherein the exosomes are identified by biomarker detection. Furthermore, the invention discloses the isolation of exosomes from an isolated fluid and the use of a biomarker, particularly CD24 to isolate exosomes from an isolated fluid.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: October 29, 2013
    Assignee: DKFZ Deutsches Krebsforschungszentrum, Stiftung des Offentlichen Rechts
    Inventors: Peter Altevogt, Sascha Keller
  • Patent number: 8563327
    Abstract: The present invention provides, as a novel diagnosis marker for type 1 diabetes mellitus, a type 1 diabetes mellitus diagnostic composition comprising alanyl-tRNA synthetase, glycyl-tRNA synthetase, asparaginyl-tRNA synthetase, or tryptophanyl-tRNA synthetase, a diagnostic kit comprising the same, and a diagnostic method using the same. The composition, the kit, and the method, according to the present invention, may be used for early diagnosis and confirmed diagnosis of type 1 diabetes mellitus because type 1 diabetes mellitus can be easily diagnosed from a patient sample.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: October 22, 2013
    Assignees: Seoul National University Hospital, SNU R&DB Foundation
    Inventors: Sang Gyu Park, Kyong Soo Park, Sunghoon Kim
  • Patent number: 8546095
    Abstract: The methods of the disclosure provide fluorescence-based assays for calcineurin activity, especially in isolated T cells. The methods include the stimulation of the T cells with agents that specifically target the TCR with or without influencing co-stimulatory pathways. One TCR agonist is monoclonal antibodies specific for CD3, which more precisely distinguish the inducible activity of calcineurin than does an alternative method targeting the T cell receptor (CD3) combined with CD28 costimulation. This method more accurately distinguishes between the measured level of calcineurin activity of T cells from immunosuppressed transplant recipients and normal individuals, and thus has improved diagnostic accuracy with respect to the response of an individual to immunosuppressant therapy following an organ transplant.
    Type: Grant
    Filed: January 20, 2010
    Date of Patent: October 1, 2013
    Assignee: Emory University
    Inventors: James Tumlin, Allan D. Kirk, Brian R. Roberts, Jennifer Gooch
  • Patent number: 8546092
    Abstract: An embodiment relates to a method of detecting a drug resistance in a patient comprising adding nanoparticles to sample platelets to form activated platelets containing the nanoparticles and comparing a difference in activation of the activated platelets and the sample platelets. Another embodiment relates to a method of monitoring a thrombotic risk factor in a subject in a general population comprising adding nanoparticles to sample platelets to form activated platelets containing the nanoparticles and comparing a difference in activation of the activated platelets and the sample platelets. Yet another embodiment relates to a kit comprising nanoparticles, a fluorescence dye tagged antibody and optionally a buffer, wherein the kit is configured to detect a drug resistance in a patient or a likelihood of the thrombotic risk factor in a subject in general population.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: October 1, 2013
    Assignee: University of Calcutta
    Inventors: Suryyani Deb, Anjan Dasgupta, Prabir Lahiri
  • Patent number: 8518716
    Abstract: This disclosure relates to methods of predicting and diagnosing preeclampsia and eclampsia in pregnant subjects. These methods include detecting a decrease of soluble c-kit in a sample obtained from the pregnant subject. A significantly reduced concentration of soluble c-kit in the sample as compared to a gestational age-adjusted control indicates that the pregnant subject will develop or has preeclampsia or eclampsia.
    Type: Grant
    Filed: November 29, 2010
    Date of Patent: August 27, 2013
    Assignee: University of Pittsburgh-Of the Commonwealth System of Higher Education
    Inventors: Carl A. Hubel, Janet M. Catov, Robin E. Gandley, James M. Roberts, Augustine Rajakumar
  • Patent number: 8513028
    Abstract: The present invention relates to novel uses of the MLN 51 gene or protein. The MLN 51 gene and protein is closely related to the development of rheumatoid arthritis and serve as biomarker and therapeutic target for rheumatoid arthritis, particularly chronic synovitis.
    Type: Grant
    Filed: May 8, 2007
    Date of Patent: August 20, 2013
    Assignee: Creagene Inc.
    Inventors: Jin Ah Jang, Dae Seog Lim, Hyun Soo Lee, Yong Soo Bae
  • Patent number: 8501427
    Abstract: The invention relates to antibodies, including monoclonal and polyclonal, or fragments thereof, which discriminate between the histidine and tyrosine isoforms of Complement Factor H and to their use in diagnostic methods and therapeutic treatments relating to Complement Factor H mediated diseases.
    Type: Grant
    Filed: January 23, 2008
    Date of Patent: August 6, 2013
    Assignee: University College Cardiff Consultants Limited
    Inventors: Bryan Paul Morgan, Claire Louise Harris, Svellana Hakobyan
  • Patent number: 8481273
    Abstract: A method for the detection in a body fluid of perlecan polypeptide fragments that are biomarkers of tumor metastasis, and antibodies for detecting these fragments are described. An immunoassay kit for detecting the presence of these biomarkers in a body fluid, such as serum or urine, is also described.
    Type: Grant
    Filed: June 16, 2009
    Date of Patent: July 9, 2013
    Assignee: University of Delaware
    Inventor: Mary C. Farach-Carson
  • Patent number: 8460943
    Abstract: A method of detecting liver damage in a subject comprises measuring the level of caspase-3 generated cytokeratin-18 fragments in the bodily sample. The level of measuring the level of caspase-3 generated cytokeratin-18 fragments is then correlated with liver disease progression.
    Type: Grant
    Filed: December 28, 2010
    Date of Patent: June 11, 2013
    Assignee: The Cleveland Clinic Foundation
    Inventors: Ariel E. Feldstein, Anna Wieckowska, Nizar Zein
  • Patent number: 8455263
    Abstract: The present invention relates to an assay device and a method for using such for the quantitative determination of an analyte, based on a test strip, which contains a porous test membrane allowing for capillary flow of the analyte and complexes of the analyte, a porous upstream membrane in fluid connection with the test membrane and a porous downstream membrane in fluid connection with the test membrane, wherein the test membrane contains a test site having immobilized thereon a ligand capable of reacting with the analyte and binding such to the test site, and two standard band sites having immobilized thereon known high and low concentrations of a calibrator agent capable of reacting with a label conjugate and binding such to the standard sites, wherein the upstream membrane has a site for the application of a sample to be analyzed, and has a site downstream from the sample application site for depositing label conjugates capable of reacting with the analyte and label conjugates capable of reacting with the
    Type: Grant
    Filed: December 30, 2008
    Date of Patent: June 4, 2013
    Inventor: Jin Po Lee
  • Patent number: 8450072
    Abstract: A multi-stage method for diagnosing an immunologic food sensitivity or intolerance in a companion animal. Firstly a saliva or blood spot or other non-serum bodily fluid sample is collected. The screening the saliva or blood spot or other non-serum bodily fluid sample detects the presence of at least one of IgA or IgM antibody to a particular food ingredient or composition. An immunologic food sensitivity or intolerance based on the presence of the antibody is diagnosed. Secondly a blood sample is collected and serum from the sample is screened to detect the semi-quantitative or quantitative presence of at least one of an IgA, IgM or IgG antibody or immune complex to a particular food ingredient or composition. An immunologic food sensitivity or intolerance based on the presence of the antibody or immune complex is diagnosed. Thirdly, a biologically active nutrient in relation to the animal from a molecular dietary signature is determined.
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: May 28, 2013
    Inventor: W. Jean Dodds
  • Patent number: 8450071
    Abstract: The present invention in one embodiment uses detection of isoforms of CAP37 as an early detection marker for a chronic inflammatory-associated disease. Chronic inflammatory-related diseases may include, for example, atherosclerosis, psoriasis, and osteoarthritis. The invention is also directed to isoforms of CAP37 protein having apparent molecular weights of about 135 kDa (±15 kDa) and about 100 kDa (±15 kDa) as assessed by SDS PAGE under reducing conditions, and their use as biomarkers for the presence of a chronic inflammatory-associated disease in a subject. The invention is also directed to monoclonal and/or polyclonal antibodies raised against such isoforms of CAP37 protein and kits and diagnostic tests comprising these antibodies.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: May 28, 2013
    Assignee: The Board of Regents of the University of Oklahoma
    Inventor: Heloise Anne Pereira
  • Patent number: 8450074
    Abstract: A multi-stage method for diagnosing an immunologic food sensitivity or intolerance in a companion animal. Firstly a saliva or blood spot or other non-serum bodily fluid sample is collected. The screening the saliva or blood spot or other non-serum bodily fluid sample detects the presence of at least one of IgA or IgM antibody to a particular food ingredient or composition. An immunologic food sensitivity or intolerance based on the presence of the antibody is diagnosed. Secondly a blood sample is collected and serum from the sample is screened to detect the semi-quantitative or quantitative presence of at least one of an IgA, IgM or IgG antibody or immune complex to a particular food ingredient or composition. An immunologic food sensitivity or intolerance based on the presence of the antibody or immune complex is diagnosed. Thirdly, a biologically active nutrient in relation to the animal from a molecular dietary signature is determined.
    Type: Grant
    Filed: January 11, 2010
    Date of Patent: May 28, 2013
    Inventor: W. Jean Dodds
  • Patent number: 8445293
    Abstract: The present invention includes methods and devices for preventing interfering substances from affecting the accuracy of a lateral flow immunoassay. In preferred embodiments, a test strip includes a capturing zone that includes at least one mobile capturing reagent that separates at least one interfering substance from the analyte. The capturing zone is preferably located upstream of the sample application zone. In some embodiments, the reagent/conjugate zone is also located upstream of the sample application zone. The capturing zone may be located upstream, downstream, or overlapping with the reagent/conjugate zone in these embodiments. In other preferred embodiments, one or more mobile capturing reagents are included in the elution medium/running buffer. In yet other embodiments, the capturing reagent is incorporated into a sample collection device of a sample collection system, preferably separate from the chromatographic test strip. A lysis zone is also included in some preferred embodiments.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: May 21, 2013
    Assignee: Rapid Pathogen Screening, Inc.
    Inventors: Uma Mahesh Babu, Franz Aberl, Marcus Scheibenzuber, Robert P. Sambursky, Robert W. VanDine, Jose S. Sambursky
  • Patent number: 8440463
    Abstract: Disclosed is a method for predicting the risk of developing renal failure or mortality for a subject suffering from diabetes mellitus. More specifically, a method is disclosed for predicting the risk of developing renal failure for a subject suffering from diabetes mellitus, the method including the steps of determining the amounts of PLGF and sFlt-1 in a sample of a subject suffering from diabetes mellitus and comparing the amounts of PLGF and sFlt-1 determined with reference amounts of PLGF and sFlt-1, whereby the risk of developing renal failure is predicted. Also disclosed are diagnostic devices and kits for carrying out the aforementioned methods.
    Type: Grant
    Filed: October 21, 2010
    Date of Patent: May 14, 2013
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Georg Hess, Andrea Horsch, Dietmar Zdunek
  • Patent number: 8426210
    Abstract: Disclosed herein are antibodies, systems and methods for assessing the risk of hemolysis following a blood transfusion with crossmatch incompatible blood. The disclosure provides a method for determining the relative hemolytic index and therefore the risk of post-transfusion hemolysis for said patient.
    Type: Grant
    Filed: October 20, 2010
    Date of Patent: April 23, 2013
    Assignee: New York Blood Center, Inc.
    Inventor: Gregory R. Halverson
  • Patent number: 8415113
    Abstract: A procedure for the identification of a functional disorder of the pancreas by the use of parts of all iso-enzymes of the pancreas elastase and of synthetic amino-acid sequences as antigens for obtaining specific antibodies, as well as their use in immuno-chemical test procedures.
    Type: Grant
    Filed: September 3, 1999
    Date of Patent: April 9, 2013
    Assignee: R-Biopharm AG
    Inventors: Hans-Werner Heinrich, Rainer Kleinert, Udo Meyer, Heinz-Jürgen Wagner
  • Patent number: 8409878
    Abstract: A method of detecting liver damage in a subject comprises measuring the level of caspase-3 generated cytokeratin-18 fragments in the bodily sample. The level of measuring the level of caspase-3 generated cytokeratin-18 fragments is then correlated with liver disease progression.
    Type: Grant
    Filed: December 28, 2010
    Date of Patent: April 2, 2013
    Assignee: The Cleveland Clinic Foundation
    Inventors: Ariel E. Feldstein, Anna Wieckowska, Nizar Zein
  • Patent number: 8409819
    Abstract: The present invention provides methods, assays, and kits for predicting or stratifying the risk of celiac disease (CD) based upon HLA-DQ genotype and/or anti-flagellin antibody levels. Such risk prediction or stratification can provide benefits to family members of CD patients, to a subset of patients who are being evaluated clinically for CD, and to researchers, who can utilize this strategy to establish inclusion criteria for participation in research studies investigating potential preventive interventions.
    Type: Grant
    Filed: February 25, 2009
    Date of Patent: April 2, 2013
    Assignee: Nestec S.A.
    Inventor: Derren M. Barken
  • Patent number: 8394600
    Abstract: Compositions, methods and devices for the detection of anti-lipoidal antibodies and the diagnosis of disease, for example, syphilis, are described. In particular, a method for immobilizing a lipoidal antigen, comprising cardiolipin, lecithin, and cholesterol, on a solid support (such as a nitrocellulose membrane) is described. The ability to immobilize a lipoidal antigen on a membrane satisfies a long-felt need for a membrane-based assay for the detection of anti-lipoidal antibodies. Also described are immunoassay devices for concurrently performing treponemal and non-treponemal tests for syphilis.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: March 12, 2013
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventor: Arnold R. Castro
  • Patent number: 8383410
    Abstract: The invention concerns an internal standard used to quantitative analysis of the risk of humoral (i.e. vascular) transplant rejection. The internal standard consists of a stable composition of the C4d complement bound to a carrier consisting of erythrocytes or microparticles. The invention also concerns a method for analyzing in vitro the risk of humoral organ transplant rejection, which consists in determining the amount of component of C4d component fixed on the erythrocytes contained in a blood sample from a patient.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: February 26, 2013
    Assignee: Universite de Reims Champagne-Ardenne
    Inventors: Jacques Henri Max Cohen, Brigitte Reveil, Aymric Kisserli, Fadi Haidar, Béatrice Donvito
  • Patent number: 8377649
    Abstract: The present invention relates to methods and kits for diagnosing, ascertaining the clinical course of myelodysplastic syndrome (MDS) and ascertaining response to a therapy regimen of myelodysplastic syndrome. Specifically the invention provides methods and kits useful in the diagnosis and determination of clinical parameters associated with MDS based on surface markers unique to MDS.
    Type: Grant
    Filed: February 1, 2011
    Date of Patent: February 19, 2013
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Jonni Moore, Sindhu Cherian, Adam Bagg